Pharmaceutical Industry Websites

The following sites are sponsored by the manufacturers of these pharmaceutical agents:

“Treat to Target” and “Use VFA” in 2017

April 23, 2017 @ 8:50 pm
posted by Dr Ginther

Clinical Osteoporosis 2017, NOF and ISCD joint meeting had a different emphasis this year.  Fracture Risk, rather than Bone Mineral Density (BMD) is now the key metric.  Several speakers emphasizd the importance of VFA in making the diagnosis of Clinical Osteoporosis.  This is something I have presented in poster exhibits 2015, 2016 and 2017.  I am now mainstream!

“Treat to Target” was the big new message this year.  We should set a target of decreased Fracture Risk for each patient and alter treatment until we reach it.  This has been routine for years in diabetes, hypertension, cholesterol, etc.  This is recognition that Osteoporosis is a chronic disease that we can control, but never cure, just like many others.

Take Control Naturally is the necessary first step, as I have outlined over the last few months.  This is often sufficient for prevention and in mild disease.

Advanced Osteoporosis, especially after fragility fractures, or vertebral compression fractures seen on VFA, is usually beyond nutrition and exercise only.  This will usually require medications to significantly reduce fracture risk.

The huge change is the recommendation to use an Anabolic medication first, to markedly reduce fracture risk, when BMD is very low or multiple fractures have already occured.  Then follow up with an Antiresorptive to maintain a low fracture risk.  Traditionally Medicare and other insurances have demanded we try Antiresorptives first to maintain bone as it is, even when multiple fractures have proven the bone to NOT be good enough at curent BMD.

We are entering a new age of Fracture Prevention!!

Jay Ginther, MD

Leave a Reply